The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy

被引:77
作者
Gulcebi, Medine Idrizoglu [1 ]
Ozkaynakci, Aydan [1 ]
Goren, Mehmet Zafer [1 ]
Aker, Rezzan Gulhan [1 ]
Ozkara, Cigdem [2 ]
Onat, Filiz Yilmaz [1 ]
机构
[1] Marmara Univ, Sch Med, Dept Pharmacol, TR-34668 Istanbul, Turkey
[2] Istanbul Univ, Dept Neurol, Cerrahpasa Med Fac, Istanbul, Turkey
关键词
Lamotrigine; Genetic polymorphism; Glucuronidation; Pharmacogenomics; Pharmacotherapy; ANTIEPILEPTIC DRUGS; GLUCURONIDATION; PHARMACOKINETICS; PREGNANCY; POPULATION; PLASMA;
D O I
10.1016/j.eplepsyres.2011.01.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Lamotrigine (LTG) which has a widespread use in epilepsy treatment as an antiepileptic agent is metabolized by UDP-glucuronosyl transferase (UGT) enzymes. In this study, single nucleotide polymorphisms, P24T and L48V, of the UGT1A4 enzyme have been investigated in a Turkish population of patients with epilepsy (n=131) by comparing serum levels of LTG of wild type and polymorphic subjects. High performance liquid chromatography (HPLC) was used to measure serum concentrations of LTG. The P24T and L48V polymorphisms of the UGT1A4 enzyme were analyzed with a matrix assisted laser desorption-time of flight (MALDI-TOF) mass spectrometry method. The frequencies of the heterozygous alleles for L48V or P24T polymorphisms were 22.4% and 3.8%, respectively. L48V polymorphism was found to decrease the serum concentration of LTG in patients on monotherapy or polytherapy. The LTG levels of non smoking monotherapy patients were 52% lower for the L48V polymorphism than for wild type alleles. Also the LTG levels were significantly lower for non smoking or smoking polymorphic alleles than for normal. The high frequency of the L48V polymorphism detected in the Turkish population indicates that LTG dose adjustments in patients with the UGT1A4 L48V polymorphic enzyme should be taken into account. (c) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [41] UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems
    Haslemo, T.
    Loryan, I.
    Ueda, N.
    Mannheimer, B.
    Bertilsson, L.
    Ingelman-Sundberg, M.
    Molden, E.
    Eliasson, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (02) : 221 - 227
  • [42] No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants*2(P24T) or*3(L48V) in Norwegian patients
    Shirzadi, Maryam
    Reimers, Arne
    Helde, Grethe
    Sjursen, Wenche
    Brodtkorb, Eylert
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2017, 45 : 169 - 171
  • [43] Human UGT1A4 and UGT1A3 Conjugate 25-Hydroxyvitamin D3: Metabolite Structure, Kinetics, Inducibility, and Interindividual Variability
    Wang, Zhican
    Wong, Timothy
    Hashizume, Takanori
    Dickmann, Leslie Z.
    Scian, Michele
    Koszewski, Nicholas J.
    Goff, Jesse P.
    Horst, Ronald L.
    Chaudhry, Amarjit S.
    Schuetz, Erin G.
    Thummel, Kenneth E.
    ENDOCRINOLOGY, 2014, 155 (06) : 2052 - 2063
  • [44] Association of CYP2C19 and UGT1A4 polymorphisms with voriconazole-induced liver injury
    Song, Yan
    Jia, Miao-xin
    Yang, Guang
    Feng, Xin-yuan
    Yin, Dong-hong
    Kang, Jian-bang
    Zhao, Qiang
    Duan, Jin-ju
    PERSONALIZED MEDICINE, 2020, 17 (01) : 15 - 22
  • [45] The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine
    Hattori, Saki
    Suda, Akira
    Miyauchi, Masatoshi
    Shiraishi, Yohko
    Saeki, Takashi
    Fukushima, Tadashi
    Fujibayashi, Mami
    Tsujita, Natsuki
    Ishii, Chie
    Ishii, Norio
    Moritani, Tosiho
    Saigusa, Yusuke
    Kishida, Ikuko
    BMC PSYCHIATRY, 2020, 20 (01)
  • [46] Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer
    Fukuda, Minoru
    Okumura, Manabu
    Iwakiri, Tomomi
    Arimori, Kazuhiko
    Honda, Takuya
    Kobayashi, Kazuma
    Senju, Hiroaki
    Takemoto, Shinnosuke
    Ikeda, Takaya
    Yamaguchi, Hiroyuki
    Nakatomi, Katsumi
    Matsuo, Nobuko
    Mukae, Hiroshi
    Ashizawa, Kazuto
    THORACIC CANCER, 2018, 9 (01) : 51 - 58
  • [47] Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
    Wood, Kelly E.
    Palmer, Kendra L.
    Krasowski, Matthew D.
    DATA IN BRIEF, 2021, 39
  • [48] Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy
    Franco, Valentina
    Gatti, Giuliana
    Mazzucchelli, Iolanda
    Marchiselli, Roberto
    Fattore, Cinzia
    Rota, Paola
    Galimberti, Carlo Andrea
    Capovilla, Giuseppe
    Beccaria, Francesca
    De Giorgis, Valentina
    Landmark, Cecilie Johannessen
    Perucca, Emilio
    EPILEPSIA, 2020, 61 (07) : E79 - E84
  • [49] Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery
    Paul, Friedemann
    Veauthier, Christian
    Fritz, Georg
    Lehmann, Thomas-Nicolas
    Aktas, Orhan
    Zipp, Frauke
    Meencke, Heinz-Joachim
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2007, 16 (06): : 479 - 484
  • [50] The Efficacy of Lamotrigine and Levetiracetam Therapy on Serum Lipid Profile in Epilepsy Patients
    Kamisli, Ozden
    Kaplan, Yuksel
    Kamisli, Suat
    Bakir, Meryem
    Ozcan, Cemal
    EPILEPSI, 2011, 17 (02): : 53 - 57